|

Ficlatuzumab Clinical Trials

1 actively recruiting trial across 1 location

Also known as: AV-299

Pipeline

Phase 3: 1

Top Sponsors

  • AVEO Pharmaceuticals, Inc.1

Indications

  • Recurrent Head and Neck Squamous Cell Carcinoma1
  • Metastatic Head and Neck Squamous Cell Carcinoma1
  • Cancer1

Gilbert, Arizona1 trial

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Banner MD Anderson Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.